The global immunohistochemistry market size was estimated at USD 3.42 billion in 2025 and is predicted to increase from USD 3.73 billion in 2026 to approximately USD 8.05 billion by 2035, expanding at a CAGR of 8.94% from 2026 to 2035. The immunohistochemistry market is growing as IHC is significantly used for the diagnosis of cancers; specific tumor antigens are expressed de novo or up-regulated in various types of cancers.
Immunohistochemistry continues to play a significant role in a variety of diseases, involving tumors, infectious diseases, neurodegenerative disorders, and muscle dysfunction. This technology remains an important tool for precision diagnostics, connecting molecular insights with morphological context, and its incorporation with digital pathology continues to enhance the diagnostic precision, reproducibility, and targeted patient care. Immunohistochemistry (IHC) uses antibodies to identify antigens in a tissue sample. This lab technique is a pathologist uses to check for signs of disease following a biopsy.
Artificial intelligence technology is transforming immunohistochemistry (IHC) through automating slide analysis, measuring protein expression, regulating diagnostic scoring, and also predicting IHC staining patterns completely from standard H&E images. AI-based models that use deep learning (DL) have been developed to quantify IHC images via tissue segmentation, cell delineation, and quantification of entirely relevant cells in an entire slide image. Immunohistochemistry can be further augmented through the application of deep learning and machine learning algorithms for assessing and analysing immunohistochemical markers.
| Table | Scope |
| Market Size in 2026 | USD 3.73 Billion |
| Projected Market Size in 2035 | USD 8.05 Billion |
| CAGR (2026 - 2035) | 8.94% |
| Leading Region | North America by 38% |
| Key Applications | Cancer Diagnostics, Companion Diagnostics, Biomarker Discovery, Drug Development, Translational Research, Infectious Disease Testing, Academic Research |
| Primary End Users | Hospitals, Diagnostic Laboratories, Pharmaceutical Companies, Biotechnology Firms, CROs, Academic Research Institutes |
| Key Growth Drivers | Rising cancer incidence, precision medicine adoption, companion diagnostics growth, digital pathology integration, AI-assisted pathology |
| Measurable Values | USD Millions/Units/Volume |
| Market Segmentation | By Product, By Application, By Technique, By End User, By Workflow, By Distribution Channel, By Region |
| Top Key Players | Abcam, Bio-Rad Laboratories, Inc., Merck KGaA, Agilent Technologies, Inc., Thermo Fisher Scientific Inc. |
| Segment | Share 2025 (%) |
| Antibodies | 34% |
| Reagents | 26% |
| Equipment | 18% |
| Kits | 14% |
| Consumables | 8% |
The Antibodies Segment Led the Immunohistochemistry Market in 2025
The antibodies segment contributed the largest market share of 34% in 2025, as high-quality antibodies are necessary for their high specificity and low cross-reactivity, making reliable and effective staining. Immunohistochemistry (IHC) uses antibodies to identify and analyse protein expression while maintaining the cellular characteristics, composition, and structure of native tissues.
The reagents segment held a significant share of 26% in the market, as IHC and imaging reagents are intended to improve the clarity and quality of staining output, which is significant for precise data understanding. Reagents are significant tools in the sectors of histology and cellular biology, offering detailed visualization of the localization of particular proteins in the tissue sections.
The equipment segment held a significant share of 18% in the immunohistochemistry market and is expected to grow at the fastest CAGR of 9.80% during the forecast period, as tackle increased laboratory effectiveness, advanced quality control, and simple reagent management. Equipment in Immunohistochemistry (IHC), like automated slide stainers, epitope retrieval technology, and digital scanners, transforms lab workflows.
The kits segment held a significant share of 14% in the market as they allow in situ visualization, localization, and semi-quantification of marker proteins in the tissue sections, forming a keystone technology in anatomical pathology, translational research, and healthcare organization diagnostics. This kit uses advanced technology and high-purity DAB chromogen, bringing clear, particulate staining with low background.
| Segment | Share 2025 (%) |
| Diagnostics | 48% |
| Drug Development & Research | 28% |
| Forensic Applications | 9% |
| Academic Research | 15% |
Diagnostics Segment Led the Immunohistochemistry Market in 2025
The diagnostics segment contributed the largest market share of 48%, as IHC helps the care team distinguish between different types and subtypes of a disease by identifying specific molecules within cells, known as markers. Immunohistochemistry supports the detection of proteins in tissue samples, supporting disease diagnosis and biomedical research. IHC is a highly specific and sensitive diagnostic method for diagnosing neoplastic diseases, infectious diseases, and nervous system-related diseases.
The drug development & research segment held a significant share of 28% of the market, and is expected to grow at the fastest CAGR of 9.60% during the forecast period as IHC is applied for disease diagnosis, drug discovery, and biological research. It is applicable in drug advancement to assess drug effectiveness by identifying changes in disease targets. IHC is often used in biomedical research to detect proteins of interest in various contexts, as well as in drug development.
The academic research segment held a significant share of 15% of the immunohistochemistry market, as immunohistochemistry (IHC) supports the identification of proteins in tissue samples, helping disease diagnosis and biomedical research. IHC enables cancer detection, staging, and classification, in addition to forecasting tumor prediction and understanding the response of cancer to treatment paradigms.
The forensic applications segment held a significant share of 9% of the market, as IHC analysis is significantly used for post-mortem diagnosis in a range of autopsy samples presenting lesser degrees of decomposition. IHC enables forensic pathologists to distinguish between the ante-mortem and post-mortem wounds.
| Segment | Share 2025 (%) |
| Immunofluorescence IHC | 22% |
| Chromogenic IHC | 46% |
| Multiplex IHC | 19% |
| Digital IHC | 13% |
The Chromogenic IHC Segment led the Immunohistochemistry Market in 2025
The chromogenic IHC segment held a significant share of 46% in the market, as chromogenic stains have increasing resistance to photobleaching compared to fluorochromes, which supports generating longer-lasting signals. Chromogenic detection processes provide significant compensation for greater sensitivity and a longer-lasting signal.
The immunofluorescence IHC segment contributed the second-largest immunohistochemistry market share of 22%, as fluorescent signals offer excellent three-dimensional resolution and contrast. This enables researchers to precisely determine the subcellular localization of molecules. Fluorescence imaging–driven technology is highly valuable for interrogating the structural and functional features of cells and tissues.
The multiplex IHC segment held a significant 19% share of the market and is expected to grow at the fastest CAGR of 11.40% during the forecast period. Multiplex immunohistochemistry (mIHC) allows the pursuit of multiple markers in the TME, predicting healing. Multiplex IHC enables the gathering of as much data as possible from the smallest of slides.
The digital IHC segment held a significant share of 13% in the market, as digital immunohistochemistry (IHC) converts physical tissue slides into high-resolution digital images. Its significant benefits include improved precision via automated quantification, increasing diagnostic turnaround times, and seamless isolated collaboration.
| Segment | Share 2025 (%) |
| Hospitals & Diagnostic Laboratories | 44% |
| Academic & Research Institutes | 21% |
| Pharmaceutical & Biotechnology Companies | 19% |
| Contract Research Organizations | 10% |
| Forensic Laboratories | 6% |
The Hospitals & Diagnostic Laboratories Segment led the Immunohistochemistry Market in 2025
The hospitals & diagnostic laboratories segment contributed the largest market share of 44%, as immunohistochemistry (IHC) supports the detection of proteins in tissue samples, supporting disease diagnosis and biomedical research. The technology is broadly used in tumor diagnosis, also for detecting the tissue origins of some diseases, aiding in understanding tumor behaviour, and guiding treatment results.
The academic & research institutes segment held a significant share of 21% in the immunohistochemistry market, as IHC is a highly specific and sensitive diagnostic technology for diagnosing neoplastic diseases, infectious diseases, and neurodegenerative diseases. It is applied in drug development to assess drug effectiveness by identifying transformation in disease targets. IHC provides important insights into the morphology, localization, and distribution of specific antigens in tissues.
The pharmaceutical & biotechnology companies segment held a significant share of 19% in the market, and is expected to grow at the fastest CAGR of 10.20 % during the forecast period, as immunohistochemistry (IHC) is the most significant application of immunostaining. It includes the process of selectively detecting antigens in cells of a tissue section by misusing the principle of antibodies binding particularly to antigens in biological tissues.
The contract research organizations segment held a significant share of 10% in the market, as immunohistochemistry (IHC) supports the detection of proteins in tissue samples, supporting biomedical and disease diagnosis research. CROs rely on IHC to rapidly confirm the presence, abundance, and distribution of drug targets, authenticating a therapeutic mechanism.
| Segment | Share 2025 (%) |
| Tissue Preparation | 18% |
| Antigen Retrieval | 15% |
| Blocking | 11% |
| Antibody Incubation | 24% |
| Detection & Visualization | 20% |
| Counterstaining & Mounting | 12% |
The Antibody Incubation Segment led the Immunohistochemistry Market in 2025
The antibody incubation segment held a significant share of 24% in the market, as antibody incubation in IHC allows scientists to view protein appearance while maintaining the tissue's intact functional framework. This reveals precisely where the protein is located in relation to the surrounding microenvironment. By using secondary antibodies to bind to the main antibody, IHC offers a strong signal amplification result.
The detection & visualization segment contributed the second-largest market share of 20%, and is expected to grow at the fastest CAGR of 10.10% during the forecast period, as immunohistochemistry is a controlling laboratory technology that uses antibodies to identify, localize, and visualize particular antigens in tissue sections. By using carefully designated antibodies and signal amplification technology, IHC can identify incredibly small or rare amounts of target proteins.
The tissue preparation segment held a significant share of 18% in the immunohistochemistry market, as IHC is used in histology to identify the presence of precise protein markers, which assist with precise tumor diagnosis and classification. Immunohistochemistry is a process for studying antigen localization in tissue sections using antibodies.
The antigen retrieval segment held a significant share of 15% in the market, as antigen repossession to expose epitopes in an antigen. Antigen retrieval is a significant pre-analytical step in IHC, which restores epitope accessibility subsequent to formalin fixation. Antigen retrieval technology aims to expose masked antigens by reversing the effects of tissue fixation via the use of heat and enzymes.
In 2025, North America dominated the immunohistochemistry market with a share of 38% in 2025, due to the growing burden of tumor incidence, morbidity, and mortality occurring in the emerging world. This forms part of a larger epidemiological transition in which the burden of long-term, non-communicable disease, once limited to industrial nations, is recently increasing in less developed countries. The extensive network of well-equipped hospitals and advanced diagnostic laboratories enables high daily throughput and clinical testing rates, which contribute to the growth of the market.
U.S. Market Trends
The U.S. oncologists progressively rely on accurate cancer subtyping. Immunohistochemistry (IHC) is an important standard for identifying significant biomarkers such as PD-L1, HER2, and ER/PR, which determine patient suitability for blockbuster-specific therapies and immunotherapies. The US Food and Drug Administration frequently pairs novel targeted therapies and antibody-drug conjugates (ADCs) with particular diagnostic tests.
Asia Pacific held 24% share of the immunohistochemistry market, expected to have the fastest CAGR of 10.90% during the forecast period, as increasing populations in countries such as China and India account for a considerable proportion of novel worldwide cancer cases. This increases a high demand for accurate, tissue-driven tumour identification and biomarker testing. The growing prevalence of chronic diseases, increasing geriatric population, and growing healthcare expenses, which contribute to the growth of the market.
India Market Trends
India has a huge and growing incidence of chronic diseases, a specific type of cancer. This increasing volume of cancer cases needs precise and highly specific diagnostic procedures such as IHC to accurately classify tumours and guide targeted treatment plans. As personalized and targeted cancer therapies become standard in Indian hospitals, IHC testing for significant biomarkers.
| Ecosystem Segment | Key Participants | Role in Market |
| Technology Providers | Roche Diagnostics, Agilent Technologies, Thermo Fisher Scientific, Danaher (Leica Biosystems) | Develop IHC platforms, staining systems, imaging technologies, and workflow automation |
| Product Manufacturers | Merck KGaA, Bio-Rad Laboratories, Abcam, Cell Signaling Technology, Vector Laboratories | Manufacture antibodies, reagents, detection kits, stains, and consumables |
| Service Providers | CellCarta, NeoGenomics, Labcorp, Quest Diagnostics | Offer IHC testing, biomarker analysis, pathology services, and companion diagnostic support |
| Platform Providers | Roche Diagnostics, Leica Biosystems, Agilent Technologies | Provide integrated pathology and tissue diagnostics platforms |
| CROs | ICON plc, Charles River Laboratories, IQVIA, Labcorp Drug Development | Support biomarker validation, translational research, and clinical trials using IHC |
| Software Vendors | Indica Labs, Paige AI, Philips Digital Pathology, Visiopharm | Develop digital pathology and AI-powered image analysis software |
| Research Institutions | MD Anderson Cancer Center, Mayo Clinic, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute | Conduct biomarker research and clinical validation studies |
| End-User Industries | Healthcare Providers, Pharma & Biotech, Academic Research, Clinical Diagnostics | Utilize IHC for diagnosis, drug development, and research |
R&D:
Manufacturing Processes:
Patient Services:
| Tier 1 | Tier 2 | Tier 3 | |
| Typical Market Influence | 65% | 25% | 10% |
| Tier 1 | ||||
| Company Name | Headquarters | Country | Why Relevant to This Market | Key Products/Services |
| Roche Diagnostics | Rotkreuz, Zug | Switzerland | Global leader in tissue diagnostics and companion diagnostics | Ventana IHC Systems, BenchMark Platforms, Companion Diagnostics |
| Agilent Technologies (Dako) | Santa Clara, California | United States | Strong global presence in pathology and cancer diagnostics | Dako Antibodies, Autostainers, IHC Reagents |
| Danaher Corporation (Leica Biosystems) | Deer Park, Illinois | United States | Major tissue diagnostics and pathology workflow provider | BOND IHC Systems, Digital Pathology Solutions |
| Tier 2 | ||||
| Company Name | Headquarters | Country | Why Relevant to This Market | Key Products/Services |
| Bio-Rad Laboratories | Hercules, California | United States | Established life sciences leader with growing antibody portfolio | Recombinant Antibodies, IHC Reagents |
| Abcam plc | Cambridge, England | United Kingdom | Leading research antibody supplier widely used in IHC | Primary Antibodies, Detection Reagents |
| Cell Signaling Technology | Danvers, Massachusetts | United States | Strong specialization in validated antibodies for pathology | Rabbit Monoclonal Antibodies, IHC Validation Kits |
| Tie 3 | ||||
| Company Name | Headquarters | Country | Why Relevant to This Market | Key Products/Services |
| Biocare Medical | Pacheco, California | United States | Specialized IHC and ISH diagnostics innovator | Automated Stainers, Detection Systems |
| Vector Laboratories | Newark, California | United States | Established niche provider of detection chemistries | VECTASTAIN Detection Systems, IHC Reagents |
| Genemed Biotechnologies | South San Francisco, California | United States | Focused supplier of pathology antibodies | Diagnostic Antibodies and Detection Reagents |
Strengths
Weakness
Opportunities
Threat
By Product
By Application
By Technique
By End User
By Workflow
By Distribution Channel
By Region
Principal Consultant
Rohan Patil is a seasoned market research professional with over 5+ years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.
Learn more about Rohan Patil
Reviewed By
Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.
Learn more about Aditi Shivarkar
+1 804-441-9344
